Part 6 of 6—What Happens Next For Revlimid, Pomalyst, Thalomid, and 340B?
As we described in Parts 2 and 3 of this series, in 2018, an ex-Celgene vice president responsible for the company’s 340B program compliance alleged in a whistleblower lawsuit that Celgene’s reason for limiting Revlimid, Pomalyst, and Thalomid’s distribution is “to deny access to the drugs at the [340B] ceiling price,” saving the company hundreds of millions of dollars per year.
As we described in Parts 2 and 3 of this series, in 2018, an ex-Celgene vice president responsible for the company’s 340B program compliance alleged in a whistleblower lawsuit that Celgene’s reason for limiting Revlimid, Pomalyst, and Thalomid’s distribution is “to deny access to the drugs at the [340B] ceiling price,” saving the company hundreds of millions of dollars per year.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.